Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark X Sliwkowski

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Molecular Cancer Therapeutics|July 5, 2015
Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck CancersChunrong Li, Shyhmin Huang, Eric A Armstrong, et al.
Molecular Cancer Therapeutics|April 27, 2018
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer CellsGuangmin Li, Jun Guo, Ben-Quan Shen, et al.
Molecular Biology of the Cell|September 24, 2004
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinCary D Austin, Ann M De Mazière, Paul I Pisacane, et al.
Cancer Research|August 17, 2006
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinibKendall D Carey, Andrew J Garton, Maria S Romero, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2011
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical doseAmrita V Kamath, Dan Lu, Priyanka Gupta, et al.
Cancer Immunology Research|June 1, 2016
HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune MicroenvironmentMaya Zigler, Alexei Shir, Salim Joubran, et al.
Molecular Cell|October 7, 2003
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptorsAntony W Burgess, Hyun-Soo Cho, Charles Eigenbrot, et al.
Cancer Research|May 21, 2010
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancerTeemu T Junttila, Kathryn Parsons, Christine Olsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Cancer Cell|September 3, 2002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthDavid B Agus, Robert W Akita, William D Fox, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Molecular Cancer Therapeutics|July 5, 2015
Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck CancersChunrong Li, Shyhmin Huang, Eric A Armstrong, et al.
Molecular Cancer Therapeutics|April 27, 2018
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer CellsGuangmin Li, Jun Guo, Ben-Quan Shen, et al.
Molecular Biology of the Cell|September 24, 2004
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinCary D Austin, Ann M De Mazière, Paul I Pisacane, et al.
Cancer Research|August 17, 2006
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinibKendall D Carey, Andrew J Garton, Maria S Romero, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2011
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical doseAmrita V Kamath, Dan Lu, Priyanka Gupta, et al.
Cancer Immunology Research|June 1, 2016
HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune MicroenvironmentMaya Zigler, Alexei Shir, Salim Joubran, et al.
Molecular Cell|October 7, 2003
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptorsAntony W Burgess, Hyun-Soo Cho, Charles Eigenbrot, et al.
Cancer Research|May 21, 2010
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancerTeemu T Junttila, Kathryn Parsons, Christine Olsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Cancer Cell|September 3, 2002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthDavid B Agus, Robert W Akita, William D Fox, et al.
Pageof 5